<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02948790</url>
  </required_header>
  <id_info>
    <org_study_id>PIC_05</org_study_id>
    <nct_id>NCT02948790</nct_id>
  </id_info>
  <brief_title>Auditory Nerve Monitoring Using Intra-cochlear Stimulation in Subjects With Acoustic Neuroma</brief_title>
  <acronym>NeuriStim</acronym>
  <official_title>Auditory Nerve Monitoring Using Intra-cochlear Stimulation in Subjects With Acoustic Neuroma : Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oticon Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oticon Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the auditory nerve functionality with an intraoperative&#xD;
      approach following a surgical removal of acoustic neuroma in patients with severe to profound&#xD;
      sensorineural hearing disabilities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Whatever the acoustic neuroma treatments, the patient risks a hearing loss. The global&#xD;
      strategy of hearing care aims to preserve the quality of life and patient hearing. For severe&#xD;
      to profound hearing loss and anatomical auditory nerve preservation, the cochlear implant is&#xD;
      put forward compared to the auditory brainstem implant. Indeed, cochlear implant provides&#xD;
      better speech outcomes. If cochlear implantation is not possible or no benefit for the&#xD;
      patient, the brainstem implant is the most widely used. The Neuristim device is used to&#xD;
      investigate the auditory nerve integrity following neuroma surgery or on an affected auditory&#xD;
      nerve. The Neuristim is an intra-cochlear stimulator used in an intraoperative way. The&#xD;
      intra-cochlear electrodes provide an electrical stimulation to auditory nerve fibers, and&#xD;
      auditory nerve response measurements to these electrical stimulation are recorded and&#xD;
      evaluated to determine the auditory nerve functionality. The Neuristim is a device for&#xD;
      helping surgeons to choose the most appropriate implantable solution. 2 groups of patients&#xD;
      will be involved in this study:&#xD;
&#xD;
        -  a group of 17 patients with an acoustic neuroma or a past neuroma surgically removed or&#xD;
           acoustic neuroma not requiring a surgery and with severe to profound hearing loss&#xD;
           candidate for a cochlear implant or a auditory brainstem depending on the auditory nerve&#xD;
           functionality,&#xD;
&#xD;
        -  a group of 17 patients with severe to profound hearing loss candidate for a cochlear&#xD;
           implant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2017</start_date>
  <completion_date type="Actual">April 3, 2019</completion_date>
  <primary_completion_date type="Actual">April 3, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wave V latency</measure>
    <time_frame>perioperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>perioperatively, 15 days postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impedance measurement</measure>
    <time_frame>perioperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ergonomics of the Neuristim</measure>
    <time_frame>perioperatively</time_frame>
    <description>satisfaction questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speech audiometry</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>in quiet and in noise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pure tone audiometry</measure>
    <time_frame>3 months postoperatively</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Hearing Loss, Cochlear</condition>
  <condition>Neurinoma of the Acoustic Nerve</condition>
  <arm_group>
    <arm_group_label>Neuristim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Electrical stimulation with the Neuristim and auditory nerve electrical response measurements (wave V).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Digisonic SP EVO cochlear implant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Electrical stimulation with the patient's cochlear implant and auditory nerve electrical response measurements (wave V).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuristim</intervention_name>
    <description>Stimulation at high, medium and low intensity on apical, medial and basal Neuristim electrode</description>
    <arm_group_label>Neuristim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cochlear implant</intervention_name>
    <description>Stimulation at high, medium and low intensity on apical, medial and basal Cochlear implant electrode</description>
    <arm_group_label>Digisonic SP EVO cochlear implant</arm_group_label>
    <other_name>Digisonic SP EVO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be 18 years or older&#xD;
&#xD;
          -  Patient with an acoustic neuroma already surgically removed with associated hearing&#xD;
             loss (experimental group),&#xD;
&#xD;
          -  Patient with an acoustic neuroma programmed to be surgically removed and candidates&#xD;
             for an implantable hearing rehabilitation solution (experimental group),&#xD;
&#xD;
          -  Patient with an acoustic neuroma that not need to be removed and candidate for an&#xD;
             implantable hearing rehabilitation solution (experimental group), or&#xD;
&#xD;
          -  Typical patient candidate for a cochlear implant (control group)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cochlea malformation, cochlea ossification&#xD;
&#xD;
          -  Vulnerable subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Vincent, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital University Lille-Roger Salengro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Bordeaux - Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Grenoble - A. Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Lyon - Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.oticonmedical.com</url>
    <description>oticon medical website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2016</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroma</mesh_term>
    <mesh_term>Neuroma, Acoustic</mesh_term>
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

